AI assistant
Sending…
Borregaard — Interim / Quarterly Report 2022
Oct 21, 2022
3562_rns_2022-10-21_73bb0ec3-1ce0-4bcf-b8e6-de4f2818dd12.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
| Income Statement Borregaard Group Q3 2022 | |||||
|---|---|---|---|---|---|
| 1.7-30.9 | 1.1-30.9 | 1.1-31.12 | |||
| Amounts in NOK million | 2022 | 2021 | 2022 | 2021 | 2021 |
| Operating revenues | 1 752 | 1 429 | 5 111 | 4 359 | 5 805 |
| Operating expenses | -1 318 | -1 038 | -3 832 | -3 250 | -4 433 |
| EBITDA | 434 | 391 | 1 279 | 1 109 | 1 372 |
| Depreciation property, plant and equipment | -112 | -103 | -330 | -310 | -416 |
| Amortisation intangible assets | -1 | -1 | -3 | -3 | -4 |
| Other income and expenses | 0 | 0 | 12 | 0 | 0 |
| Operating profit | 321 | 287 | 958 | 796 | 952 |
| Financial items, net | -12 | -18 | -50 | -55 | -79 |
| Profit before taxes | 309 | 269 | 908 | 741 | 873 |
| Income tax expence | -74 | -64 | -220 | -174 | -213 |
| Profit for the period | 235 | 205 | 688 | 567 | 660 |
| Profit attributable to non-controlling interests | -4 | -6 | -20 | -23 | -32 |
| Profit attributable to owners of the parent | 239 | 211 | 708 | 590 | 692 |
| Earnings per share (NOK) | 2,40 | 2,12 | 7,10 | 5,93 | 6,95 |
| EBITDA margin | 24,8 % | 27,4 % | 25,0 % | 25,4 % | 23,6 % |
| Interim condensed statement of financial position Borregaard Group | |||
|---|---|---|---|
| 30.9. | 30.6. | 31.12. | |
| Amounts in NOK million | 2022 | 2022 | 2021 |
| Assets: | |||
| Intangible assets | 84 | 86 | 89 |
| Property, plant and equipment | 4 339 | 4 273 | 4 191 |
| Right-of-use assets | 342 | 345 | 351 |
| Other assets | 240 | 237 | 339 |
| Investments in joint venture/associate company | 143 | 144 | 173 |
| Non-current assets | 5 148 | 5 085 | 5 143 |
| Inventories | 1 230 | 1 035 | 792 |
| Receivables | 1 495 | 1 469 | 1 107 |
| Cash and cash deposits | 167 | 90 | 124 |
| Current assets | 2 892 | 2 594 | 2 023 |
| Total assets | 8 040 | 7 679 | 7 166 |
| Equity and debt: | |||
| Group equity | 3 929 | 3 899 | 4 222 |
| Non-controlling interests | 79 | 76 | 84 |
| Equity | 4 008 | 3 975 | 4 306 |
| Provisions and other liabilities | 438 | 361 | 257 |
| Interest-bearing liabilities | 1 523 | 1 926 | 1 320 |
| Non-current liabilities | 1 961 | 2 287 | 1 577 |
| Interest-bearing liabilities | 641 | 272 | 224 |
| Other current liabilities | 1 430 | 1 145 | 1 059 |
| Current liabilities | 2 071 | 1 417 | 1 283 |
| Equity and liabilities | 8 040 | 7 679 | 7 166 |
| Equity ratio (%): | 49,9 % | 51,8 % | 60,1 % |
| Interim condensed cash flow statement Borregaard Group Q3 2022 | |||||
|---|---|---|---|---|---|
| 1.7-30.9 | 1.1-30.9 | 1.1-31.12 | |||
| Amounts in NOK million | 2022 | 2021 | 2022 | 2021 | 2021 |
| Profit before taxes | 309 | 269 | 908 | 741 | 873 |
| Amortisation, depreciation and impairment charges | 113 | 104 | 333 | 313 | 420 |
| Change in net working capital, etc | -111 | 8 | -713 | 82 | 256 |
| Dividend/share of profit from JV & associate company | 0 | 0 | 31 | 0 | 6 |
| Taxes paid | 1 | -3 | -137 | -61 | -124 |
| Cash flow from operating activities | 312 | 378 | 422 | 1 075 | 1 431 |
| Investments property, plant and equipment and intangible assets * | -84 | -109 | -252 | -329 | -556 |
| Investment in associate company | 0 | -110 | 0 | -110 | -145 |
| Other capital transactions | -1 | 2 | 5 | 5 | 9 |
| Cash flow from Investing activities | -85 | -217 | -247 | -434 | -692 |
| Dividends | 0 | 0 | -499 | -249 | -249 |
| Proceeds from exercise of options/shares to employees | 0 | 9 | 34 | 55 | 59 |
| Buy-back of shares | 0 | -23 | -23 | -111 | -118 |
| Gain/(loss) on hedges for net investments in subsidiaries | -76 | -6 | -156 | 11 | -14 |
| Net paid to/from shareholders | -76 | -20 | -644 | -294 | -322 |
| Proceeds from interest-bearing liabilities | 0 | 0 | 837 | 300 | 300 |
| Repayment of interest-bearing liabilities | -116 | -212 | -469 | -668 | -814 |
| Change in interest-bearing receivables/other liabilities | 51 | 1 | 119 | -5 | -1 |
| Change in net interest-bearing liablities | -65 | -211 | 487 | -373 | -515 |
| Cash flow from financing activities | -141 | -231 | -157 | -667 | -837 |
| Change in cash and cash equivalents | 86 | -70 | 18 | -26 | -98 |
| Cash and cash equivalents at beginning of period | -38 | 143 | 5 | 96 | 96 |
| Change in cash and cash equivalents | 86 | -70 | 18 | -26 | -98 |
| Currency effects cash and cash equivalents | 28 | 3 | 53 | 6 | 7 |
| Cash and cash equivalents at the end of the period | 76 | 76 | 76 | 76 | 5 |
| * Investment by category: | |||||
| Replacement investments | 59 | 56 | 187 | 208 | 398 |
| Expansion investments including investment in associate company | 25 | 163 | 65 | 231 | 303 |
| Total investments including investment in associate company | 84 | 219 | 252 | 439 | 701 |
Quarterly segment information Borregaard Group
| Operating revenues | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard | 4 785 | 5 063 | 1 372 | 1 358 | 1 260 | 1 338 | 5 328 | 1 419 | 1 511 | 1 429 | 1 446 | 5 805 | 1 615 | 1 744 | 1 752 | 5 111 |
| BioSolutions | 2 775 | 2 982 | 797 | 819 | 733 | 733 | 3 082 | 812 | 885 | 838 | 934 | 3 469 | 948 | 1 098 | 1 007 | 3 053 |
| BioMaterials | 1 661 | 1 712 | 454 | 417 | 403 | 458 | 1 732 | 523 | 482 | 468 | 405 | 1 878 | 532 | 540 | 558 | 1 630 |
| Fine Chemicals | 374 | 406 | 128 | 131 | 131 | 153 | 543 | 90 | 155 | 132 | 114 | 491 | 143 | 119 | 200 | 462 |
| Eliminations | - 25 | - 37 | - 7 | - 9 | - 7 | - 6 | - 29 | -6 | -11 | -9 | -7 | -33 | -8 | -13 | -13 | -34 |
| EBITDA | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million Borregaard |
2018 903 |
2019 1 007 |
2020 242 |
2020 361 |
2020 266 |
2020 263 |
2020 1 132 |
2021 302 |
2021 416 |
2021 391 |
2021 263 |
2021 1 372 |
2022 400 |
2022 445 |
2022 434 |
2022 1 279 |
| BioSolutions | 499 | 647 | 170 | 193 | 132 | 137 | 632 | 205 | 272 | 251 | 214 | 942 | 261 | 305 | 261 | 827 |
| BioMaterials | 312 | 234 | 46 | 101 | 91 | 80 | 318 | 64 | 102 | 91 | 27 | 284 | 97 | 91 | 101 | 289 |
| Fine Chemicals | 92 | 126 | 26 | 67 | 43 | 46 | 182 | 33 | 42 | 49 | 22 | 146 | 42 | 49 | 72 | 163 |
| Depreciations and write downs | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard | - 323 | - 418 | - 109 | - 112 | - 112 | - 110 | - 443 | -106 | -101 | -103 | -106 | -416 | -108 | -110 | -112 | -330 |
| BioSolutions | - 113 | - 183 | - 51 | - 51 | - 53 | - 51 | - 206 | -48 | -45 | -47 | -49 | -189 | -50 | -53 | -54 | -157 |
| BioMaterials | - 189 | - 203 | - 50 | - 52 | - 51 | - 50 | - 203 | -50 | -47 | -47 | -49 | -193 | -49 | -48 | -49 | -146 |
| Fine Chemicals | - 21 | - 32 | - 8 | - 9 | - 8 | - 9 | - 34 | -8 | -9 | -9 | -8 | -34 | -9 | -9 | -9 | -27 |
| Amortisation | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard | - 4 | - 4 | - 1 | - 1 | - 1 | - 2 | - 5 | -1 | -1 | -1 | -1 | -4 | -1 | -1 | -1 | -3 |
| BioSolutions | - 4 | - 4 | - 1 | - 1 | - 1 | - 2 | - 5 | -1 | -1 | -1 | -1 | -4 | -1 | -1 | -1 | -3 |
| BioMaterials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income and expenses | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard | 0 | -27 | 0 | -96 | 0 | -20 | -116 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 12 |
| BioSolutions | 0 | -16 | 0 | -90 | 0 | -7 | -97 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 12 |
| BioMaterials | 0 | -11 | 0 | -6 | 0 | -12 | -18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | - 1 | - 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit (EBIT) | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard | 576 | 558 | 132 | 152 | 153 | 131 | 568 | 195 | 314 | 287 | 156 | 952 | 291 | 346 | 321 | 958 |
| BioSolutions | 382 | 444 | 118 | 51 | 78 | 77 | 324 | 156 | 226 | 203 | 164 | 749 | 210 | 263 | 206 | 679 |
| BioMaterials Fine Chemicals |
123 71 |
20 94 |
- 4 18 |
43 58 |
40 35 |
18 36 |
97 147 |
14 25 |
55 33 |
44 40 |
-22 14 |
91 112 |
48 33 |
43 40 |
52 63 |
143 136 |
| Quarterly segment information Borregaard Group | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hedging effects & currency exposure | 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard - EBITDA hedging gains & losses | -11 | -76 | -62 | -84 | -51 | -44 | -241 | -15 | -4 | -16 | 6 | -29 | 10 | -3 | -23 | -16 |
| BioSolutions | 3 | -33 | -26 | -38 | -21 | -18 | -103 | -5 | -1 | -6 | 1 | -11 | 3 | -5 | -19 | -21 |
| BioMaterials | -3 | -37 | -30 | -39 | -25 | -22 | -116 | -8 | -3 | -8 | 4 | -15 | 5 | 1 | -4 | 2 |
| Fine Chemicals | -11 | -6 | -6 | -7 | -5 | -4 | -22 | -2 | 0 | -2 | 1 | -3 | 2 | 1 | 0 | 3 |
| Borregaard - USD EBITDA currency exposure (approx) | 194 | 203 | 177 | 198 | ||||||||||||
| Borregaard - EUR EBITDA currency exposure (approx) | 84 | 98 | 112 | 139 | ||||||||||||
| Sales revenues | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| Amounts in NOK million | 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| Borregaard | 4 705 | 4 951 | 1 347 | 1 337 | 1 229 | 1 314 | 5 227 | 1 394 | 1 491 | 1 406 | 1 424 | 5 715 | 1 591 | 1 720 | 1 723 | 5 034 |
| BioSolutions | 2 708 | 2 873 | 775 | 800 | 706 | 714 | 2 995 | 793 | 865 | 819 | 915 | 3 392 | 929 | 1 072 | 979 | 2 980 |
| BioMaterials | 1 630 | 1 679 | 445 | 407 | 395 | 448 | 1 695 | 513 | 472 | 457 | 398 | 1 840 | 521 | 530 | 546 | 1 597 |
| Fine Chemicals | 369 | 400 | 127 | 130 | 128 | 153 | 538 | 88 | 154 | 131 | 112 | 485 | 141 | 118 | 198 | 457 |
| Eliminations | - 2 | - 1 | 0 | 0 | 0 | - 1 | - 1 | 0 | 0 | -1 | -1 | -2 | 0 | 0 | 0 | 0 |
| BioSolutions | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | |
| Average gross sales price NOK per mtds | 5 654 | 6 166 | 6 885 | 7 431 | 6 701 | 6 756 | 6 951 | 7 838 | 7 709 | 7 761 | 9 244 | 8 106 | 9 780 | 10 150 | 10 479 | 10 141 |
| Volume (`000 mtds) | 468 | 470 | 115 | 106 | 99 | 96 | 416 | 90 | 100 | 92 | 84 | 366 | 81 | 90 | 84 | 255 |
| Specialities volume (`000 mtds) | 86 | 86 | 88 | 89 | ||||||||||||
| Contruction volume (`000 mtds) | 212 | 209 | 178 | 131 | ||||||||||||
| Industrial volume (`000 mtds) | 170 | 175 | 150 | 146 | ||||||||||||
| BioMaterials | ||||||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.1-30.9 | |
| 2018 | 2019 | 2020 | 2020 | 2020 | 2020 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | |
| Average gross sales price NOK per mt | 10 337 | 10 665 | 11 382 | 12 579 | 11 780 | 11 128 | 11 678 | 10 641 | 10 754 | 10 972 | 10 911 | 10 807 | 12 595 | 13 656 | 14 880 | 13 662 |
| Volume (`000 mt) | 150,1 | 153,1 | 40,0 | 33,9 | 34,2 | 40,3 | 148,4 | 47,5 | 42,4 | 40,2 | 34,3 | 164,4 | 39,4 | 36,6 | 34,7 | 110,7 |
| High specialised as % of total cellulose product sales volum | 62 % | 73 % | 77 % | 79 % | ||||||||||||
More from Borregaard
Transaction in Own Shares
2026
May 27
Transaction in Own Shares
2026
May 27
Transaction in Own Shares
2026
May 20
Transaction in Own Shares
2026
May 20
Transaction in Own Shares
2026
May 8
Director's Dealing
2026
Apr 30
Director's Dealing
2026
Apr 30
Director's Dealing
2026
Apr 29
Director's Dealing
2026
Apr 29
Interim / Quarterly Report
2026
Apr 29